Crystal Pharmatech
Christine Padula is a Research Scientist at Crystal Pharmatech since 2023, bringing prior experience as an Operations Engineer at Messer Americas from 2021 to 2023, where responsibilities included project execution and account management in technical sales. Prior to this, Christine interned in Research and Development at Colgate-Palmolive, focusing on the creation of novel oral care products and advancing polymeric biomaterials, resulting in multiple invention records and pending patents. Early career experiences include a sales representative role at Vector Marketing, showcasing strong sales and leadership skills, and a research assistant position at Rutgers University, focusing on drug delivery systems and personal care product formulations. Christine holds both a Bachelor of Science and a Master of Science in Chemical Engineering from Rutgers University.
Crystal Pharmatech
Established in 2010, Crystal Pharmatech is a specialized CRO/CDMO, excelling in crystal form and formulation services. Our exceptional track record includes supporting 1,000 clients and collaborating on over 2,000 compounds, showcasing our expertise in solid-state research, crystallization, pre-formulation, formulation development, and manufacturing. With a global presence encompassing three strategically located R&D centers in Suzhou (China), New Jersey (USA), and Toronto (Canada), we are powered by a skilled team of around 250 professionals. As a leader in both conventional and enabling formulation technologies, including amorphous solid dispersion, we take pride in our cGMP facilities, strictly adhering to the rigorous standards set by the FDA, EMA, and NMPA. Our integrated service encompasses the entire new drug development journey, from developability assessment and solid form screening to pre-formulation, formulation development, and CTM and commercial manufacturing. Introducing our pioneering Mol2Med program, designed to expedite small molecule lead compounds or preclinical candidates into Phase I and beyond, with unparalleled efficiency and precision. This 3-step First-Time-Right approach begins at the lead optimization/PCC stage: Step 1: Developability Assessment to guide API form selection and formulation design. Step 2: Solid form screening/selection and Preformulation. Step 3: Formulation development and CTM manufacturing, including packaging, labeling, and shipping to the clinical site. This innovative approach guarantees a robust API form and a scalable manufacturing process, culminating in a First-Time-Right formulation for Phase I. Streamlining the transition to future clinical studies upon Phase I success, our First-Time-Right approach sets the foundation for optimized drug development and success beyond.